Analysts and investors seem to be taking FDA at its word when it comes to the promise of a breakthrough product, but those promising therapies also will have to see long-term success for the program to be validated.
There is little commercial evidence so far, and the first wave of products didn’t necessarily have the full range of benefit from the program, as many of the designations came...